This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Werewolf (HOWL) Up on Deal With Merck for Solid Tumor Study
by Zacks Equity Research
Werewolf Therapeutics (HOWL) inks a collaboration and supply agreement with Merck to evaluate its candidate, WTX-124, in combination with Keytruda, for treating solid tumors. Stock up.
Zacks.com featured highlights include: SunOpta, Rent-A-Center, Sterling Construction, Vertex Pharmaceuticals and Alto Ingredients
by Zacks Equity Research
Zacks.com featured highlights include: SunOpta, Rent-A-Center, Sterling Construction, Vertex Pharmaceuticals and Alto Ingredients
Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Inside the top-ranked stocks that can beat earnings estimates in their next releases.
Glaxo's (GSK) Jemperli Gets FDA Approval for New Indication
by Zacks Equity Research
The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating patients with mismatch repair-deficient recurrent/advanced solid tumors. This is the second approved indication for the drug.
Mei (MEIP) Begins Phase III Study for B-Cell Malignancies
by Zacks Equity Research
Mei Pharma (MEIP) doses first patient in phase III study to evaluate zandelisib plus rituximab in follicular lymphoma or marginal zone lymphoma.
Aurinia (AUPH) Adds Two Candidates, Boosts Immunology Pipeline
by Zacks Equity Research
Aurinia (AUPH) acquires two pre-clinical, novel pipeline programs for the treatment of rare autoimmune, fibrotic and kidney diseases. Yet, the stock price declines.
Delta Variant Catches Up with the Stock Market
by Mark Vickery
Today, worries about growth and demand, at least partially caused by the Delta variant of Covid-19 manifesting in pockets of America.
Travere (TVTX) Announces Data on Rare Kidney Disease Drug
by Zacks Equity Research
Travere (TVTX) announces positive interim data from the ongoing study of its investigational candidate, sparsentan, for the treatment of IgAN, a rare kidney disorder. Resultantly, the stock rises
Moderna (MRNA) Begins Rare Disease Study, Inks Supply Agreement
by Zacks Equity Research
Moderna (MRNA) doses first patient in phase I/II study with mRNA-3705 for the treatment of a rare multi-organ disorder. The company also revises the supply agreement with the Canadian Government for its COVID vaccine.
Sesen's (SESN) Bladder Cancer Drug Vicineum Gets CRL From FDA
by Zacks Equity Research
Sesen's (SESN) biologics license application filed for Vicineum to treat BCG-unresponsive non-muscle invasive bladder cancer fails to secure approval. The stock declines resultantly.
Pfizer (PFE) Gets Fast Track Tag for Wilson Disease Candidate
by Zacks Equity Research
The FDA bestows a Fast Track designation to Pfizer (PFE) and partner Vivet Therapeutics' clinical-stage gene therapy, VTX-801, for the treatment of Wilson disease.
Organon's (OGN) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Organon's (OGN) earnings and revenues beat estimates in the second quarter of 2021. Stock up in pre-market trading.
Perrigo (PRGO) Q2 Earnings Lag, Sales Hurt by Weak Cold Season
by Zacks Equity Research
Perrigo (PRGO) reports dismal second-quarter 2021 results. Stock down.
ChemoCentryx (CCXI) Q2 Loss Wider Than Expected, Sales Down
by Zacks Equity Research
ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the second quarter and misses on sales.
Axsome (AXSM) Q2 Earnings Top, AXS-05 Approval Likely Delayed
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports narrower-than-expected Q2 loss. Yet, share price falls steeply after it notified of a potential delay in the approval of AXS-05 for major depressive disorder
QIAGEN (QGEN) Gains FDA's EUA for SARS CoV-2 Antigen Test
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach SARS CoV-2 Antigen Test can detect SARS CoV-2 antigens in 2-15 minutes and can process an average of 30 swab samples per hour.
Viatris (VTRS) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Viatris (VTRS) beats on Q2 earnings and sales. The company raises annual guidance.
Bayer's (BAYRY) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2021.
Amicus (FOLD) Q2 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Amicus (FOLD) reports narrower-than-expected Q2 loss. The sales figure also beat estimates. Following encouraging results and positive progress with pipeline candidates, the stock rises.
Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Vertex Pharma and Twilio highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Vertex Pharma and Twilio highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Vertex Pharmaceuticals (VRTX)
by Kevin Cook
Scientific innovation in the treatment of cystic fibrosis bolsters success and pipeline confidence
Horizon's (HZNP) Q2 Earnings and Revenues Beat, Stock Up
by Zacks Equity Research
Horizon (HZNP) beats on both earnings and revenues in Q2. Sales soared on account of the relaunch of the thyroid eye disease drug Tepezza. As a result, stock rises.
Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down
by Zacks Equity Research
Clovis (CLVS) reports wider-than-expected loss for second-quarter 2021. Sales of the company's sole marketed drug, Rubraca, decreased year over year due to COVID-19 impacts.